In comparison to invasive techniques used for sourcing DNA such as the taking of blood samples, the buccal swabs procedure is quick and painless and can be carried out by non-trained users
DNA Research Innovation (DRI), a supplier of products for manual
and automated nucleic acid extraction, has announced the signing
of a new OEM distribution agreement with buccal swab innovator
DRI will non-exclusively supply for re-sale its
ChargeSwitch genomic DNA purification kits for buccal cells to
Isohelix for manual and automated use.
Buccal swabs are widely
used to non-invasively remove cheek lining cells from individuals
which are then processed to extract DNA.
This methodology is
routinely used worldwide for criminal justice DNA databasing,
clinical genotyping and lifestyle genotyping.
In comparison to
invasive techniques used for sourcing DNA such as the taking of
blood samples, the buccal swabs procedure is quick and painless
and can be carried out by non-trained users.
Due to the rapid
expansion of clinical and lifestyle genotyping and the wider use
of national criminal databases, there is a growing need for
rapid, high yield and effective methods for DNA extraction from
buccal swabs to replace blood based protocols.
DRI markets rapid
DNA and RNA purification kits based on its patented ChargeSwitch
ChargeSwitch protocols do not require the use of PCR
inhibitors such as alcohols, concentrated chaotropic salts or
organic solvents and has received leading endorsements in the
application of DNA extraction from buccal swabs.
the T-Swab buccal swab and Autohelix methodology for high yield
and high throughput swab processing.
This new relationship is
aimed to further enable Isohelix to penetrate existing and novel
US and European markets.
"This agreement gives us additional
exposure and methods of distribution into the forensic and
clinical genotyping community," said Simon Douglas, CEO of
"The combination of the high yield T-Swab and
innovative ChargeSwitch technology will greatly enhance
throughput and yield for major laboratories.
relationship is very much in line with our OEM strategy and we
look forward to seeing an expansion of our existing customer
"Within the nucleic acid purification market,
DRI's technology is very unique and very effective,"
added Ernest Poku, CEO of Isohelix.
"The high DNA yield and
simplicity of protocols for both manual and automated extraction
made DRI a strong partner of choice for us.
This agreement will
be beneficial to both parties."